Parkinson's disease other imaging findings: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
 
(6 intermediate revisions by the same user not shown)
Line 7: Line 7:


==Overview==
==Overview==
'''PET scan''': In [[PET scan]] we can see that the uptake of [18F]-flurodopa tracer in reduce in the [[Caudate nucleus|caudate]] and [[putamen]] in [[Parkinson's disease|PD]] patients.
'''DaTscan''': This technique can help us differentiate healthy individuals or patients with [[essential tremor]] from diseases with nigrostriatal degeneration ([[Parkinson's disease|PD]], [[Multiple system atrophy|MSA]], [[Progressive supranuclear palsy|PSP]], and cortical degeneration).
'''Sonography''': In [[sonography]] of [[Parkinson's disease|PD]] patient’s [[brain]] we can see hyperechogenicity of the [[STN]].


==Other Imaging Findings==
==Other Imaging Findings==


'''PET scan''': In [[PET scan]] we can see that the uptake of [18F]-flurodopa tracer in reduce in the [[Caudate nucleus|caudate]] and [[putamen]] in [[Parkinson's disease|PD]] patients.<ref name="pmid20669302">{{cite journal |vauthors=Teune LK, Bartels AL, de Jong BM, Willemsen AT, Eshuis SA, de Vries JJ, van Oostrom JC, Leenders KL |title=Typical cerebral metabolic patterns in neurodegenerative brain diseases |journal=Mov. Disord. |volume=25 |issue=14 |pages=2395–404 |date=October 2010 |pmid=20669302 |doi=10.1002/mds.23291 |url=}}</ref>
* '''PET scan''': In [[PET scan]] we can see that the uptake of [18F]-flurodopa tracer in reduce in the [[Caudate nucleus|caudate]] and [[putamen]] in [[Parkinson's disease|PD]] patients.<ref name="pmid20669302">{{cite journal |vauthors=Teune LK, Bartels AL, de Jong BM, Willemsen AT, Eshuis SA, de Vries JJ, van Oostrom JC, Leenders KL |title=Typical cerebral metabolic patterns in neurodegenerative brain diseases |journal=Mov. Disord. |volume=25 |issue=14 |pages=2395–404 |date=October 2010 |pmid=20669302 |doi=10.1002/mds.23291 |url=}}</ref>


[[Image:PET scan Parkinson's Disease.jpg|thumb|left|200px|18F PET scan shows decreased dopamine activity in the [[basal ganglia]], a pattern which aids in diagnosing Parkinson's disease.]]
[[Image:PET scan Parkinson's Disease.jpg|thumb|left|200px|18F PET scan shows decreased dopamine activity in the [[basal ganglia]], a pattern which aids in diagnosing Parkinson's disease.]]
<br clear="left" />
<br clear="left" />
* '''DaTscan''': This technique can help us differentiate healthy individuals or patients with [[essential tremor]] from diseases with nigrostriatal degeneration ([[Parkinson's disease|PD]], [[Multiple system atrophy|MSA]], [[Progressive supranuclear palsy|PSP]], and cortical degeneration).<ref name="pmid22014434">{{cite journal |vauthors=Stoessl AJ, Martin WW, McKeown MJ, Sossi V |title=Advances in imaging in Parkinson's disease |journal=Lancet Neurol |volume=10 |issue=11 |pages=987–1001 |date=November 2011 |pmid=22014434 |doi=10.1016/S1474-4422(11)70214-9 |url=}}</ref><ref name="pmid20019219">{{cite journal |vauthors=Kägi G, Bhatia KP, Tolosa E |title=The role of DAT-SPECT in movement disorders |journal=J. Neurol. Neurosurg. Psychiatry |volume=81 |issue=1 |pages=5–12 |date=January 2010 |pmid=20019219 |doi=10.1136/jnnp.2008.157370 |url=}}</ref>
* '''Sonography''': In [[sonography]] of [[Parkinson's disease|PD]] patient’s [[brain]] we can see hyperechogenicity of the [[STN]].<ref name="pmid18394965">{{cite journal |vauthors=Gaenslen A, Unmuth B, Godau J, Liepelt I, Di Santo A, Schweitzer KJ, Gasser T, Machulla HJ, Reimold M, Marek K, Berg D |title=The specificity and sensitivity of transcranial ultrasound in the differential diagnosis of Parkinson's disease: a prospective blinded study |journal=Lancet Neurol |volume=7 |issue=5 |pages=417–24 |date=May 2008 |pmid=18394965 |doi=10.1016/S1474-4422(08)70067-X |url=}}</ref>


==References==
==References==

Latest revision as of 19:09, 28 November 2018

Parkinson's disease Microchapters

Home

Patient Information

Overview

Historical Perspective

Pathophysiology

Causes

Differentiating Parkinson's disease from other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Neurocognitive Disorder Due to Parkinson's Disease

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Parkinson's disease other imaging findings On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Parkinson's disease other imaging findings

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Parkinson's disease other imaging findings

CDC on Parkinson's disease other imaging findings

Parkinson's disease other imaging findings in the news

Blogs on Parkinson's disease other imaging findings

Directions to Hospitals Treating Parkinson's disease

Risk calculators and risk factors for Parkinson's disease other imaging findings

Please help WikiDoc by adding more content here. It's easy! Click here to learn about editing.

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

PET scan: In PET scan we can see that the uptake of [18F]-flurodopa tracer in reduce in the caudate and putamen in PD patients.

DaTscan: This technique can help us differentiate healthy individuals or patients with essential tremor from diseases with nigrostriatal degeneration (PD, MSA, PSP, and cortical degeneration).

Sonography: In sonography of PD patient’s brain we can see hyperechogenicity of the STN.

Other Imaging Findings

18F PET scan shows decreased dopamine activity in the basal ganglia, a pattern which aids in diagnosing Parkinson's disease.


  • DaTscan: This technique can help us differentiate healthy individuals or patients with essential tremor from diseases with nigrostriatal degeneration (PD, MSA, PSP, and cortical degeneration).[2][3]

References

  1. Teune LK, Bartels AL, de Jong BM, Willemsen AT, Eshuis SA, de Vries JJ, van Oostrom JC, Leenders KL (October 2010). "Typical cerebral metabolic patterns in neurodegenerative brain diseases". Mov. Disord. 25 (14): 2395–404. doi:10.1002/mds.23291. PMID 20669302.
  2. Stoessl AJ, Martin WW, McKeown MJ, Sossi V (November 2011). "Advances in imaging in Parkinson's disease". Lancet Neurol. 10 (11): 987–1001. doi:10.1016/S1474-4422(11)70214-9. PMID 22014434.
  3. Kägi G, Bhatia KP, Tolosa E (January 2010). "The role of DAT-SPECT in movement disorders". J. Neurol. Neurosurg. Psychiatry. 81 (1): 5–12. doi:10.1136/jnnp.2008.157370. PMID 20019219.
  4. Gaenslen A, Unmuth B, Godau J, Liepelt I, Di Santo A, Schweitzer KJ, Gasser T, Machulla HJ, Reimold M, Marek K, Berg D (May 2008). "The specificity and sensitivity of transcranial ultrasound in the differential diagnosis of Parkinson's disease: a prospective blinded study". Lancet Neurol. 7 (5): 417–24. doi:10.1016/S1474-4422(08)70067-X. PMID 18394965.

Template:WH Template:WS